Cardiology

New data suggest 90 days following an initial ACS event is the greatest time of likelihood for another high-risk event. How can this inform cardiovascular research?

Marc Bonaca, MD, explains the value of new assessments made in the pivotal peripheral artery disease clinical trial.

A cardiologist and wellness expert discusses new findings showing more than one-third of her peers were burnt out from experiences during the pandemic.

The Duke investigators return to discuss the pivotal study of rivaroxaban in peripheral artery disease.

There is no clear threshold for consumption leading to an AFib event.

Patients with a preserved ejection fraction saw a significant reduction in risk for cardiovascular-related adverse events and mortality.

Final thoughts from expert KOLs regarding treatment decisions and how they relate to patient accessibility when manage dyslipidemia.

Importance of shared decision making and value-based care when making treatment decisions for cardiovascular patients.

Results of a well-being study presented at ACC.21 paint a grim picture related to the impact of COVID-19 on burnout and well-being among cardiology professionals. We sat down with lead investigator Laxmi Mehta, MD, for further perspective on the issue.

An ACC.21 study assessing the risk of adverse cardiovascular and renal outcomes found a graded increase in risk across the entire glycemic spectrum, including prediabetic levels.

New phase 2 data show the potential of the biologic in patients at risk of acute pancreatitis progression, but with a need for better variable understanding.

Investigators discuss recently-published secondary sex-based assessments into PCI treatment, as well as their contribution to cardiovascular research action points that lessen the field's disparities.

Patients on atorvastatin experienced similar rates of adjudicated venous thromboembolism and all-cause mortality compared to placebo.

The 1-year follow-up of the REALITY trial presented at ACC undermines previously reported 30-day findings showing noninferiority to liberal transfusions.

DARE-19 data show a slight improvement in outcomes among hospitalized COVID-19 patients receiving the SGLT-2 inhibitor—showing the cardiovascular drug class is safe in patients with the pandemic virus.

The TALOS AMI study suggests DAPT de-escalation 30 days after PCI was associated with lower rates of bleeding and the study's composite endpoint of cardiovascular death, MI, or stroke.

The SGLT-2 inhibitor drug class is expanding into treatment indications experts could not have predicted. Learn how DAPA-HF contributed to the understanding of dapagliflozin.

Data from the FLOWER-MI study suggest fractional flow reserve-guided PCI provided no benefit versus angiography-guided PCI for risk of death, MI, or urgent revascularization among STEMI patients with multivessel disease.

As part of our coverage of ACC.21, Practical Cardiology reached out to Deepak Bhatt, MD, MPH, to learn about his reaction to the latest analysis of the STRENGTH trial and how it might impact how REDUCE-IT results are interpreted.

A post-hoc analysis sought to elucidate the contradictory results between the STRENGTH and REDUCE-IT trials.

A secondary analysis of the STRENGTH trial from ACC.21 is calling into question the apparent CV benefits of other fish oil-based agents in patients with elevated triglycerides.

Older patients who maintained the multi-domain rehabilitation program saw improvements in various markers of physical function.

An analysis of STOP AF First presented at ACC.21 details the quality of life improvements observed with cryoablation versus antiarrhythmic drugs as initial treatment for atrial fibrillation.

Investigators discuss observed outcomes in females with high-risk PCI treatment, and their continued underrepresentation in pharmacologic studies.

Improvements in patient symptoms, function, and quality of life were not sustained once treatment was discontinued.

Though the combination heart failure therapy did provide overall benefit versus ramipril in post-heart attack patients, the rate of events reduced was not considered significant.

The first episode of the Heart Trials podcast series focuses on new ACC 2021 research into aspirin dosages for reduced cardiovascular event risk.

The ADAPTABLE study from DCRI suggests patients with existing CVD saw similar outcomes whether they were receiving 81 mg or 325 mg aspirin, but also suggests patients with the higher dose were more likely to discontinue therapy.

Data suggests that the non-vitamin K antagonist blood thinner may be used as default treatment among post-operative patients in need of oral anticoagulation.

The low-dose cohort of RP-A501 conferred cardiac LAMP2B transgene expression.